Founded in 2008, Gubra is a privately-held biotech company with two primary areas of business: pre-clinical contract research (CRO) services and proprietary early target and drug discovery programs.
Gubra’s focus is the metabolic space (obesity, diabetes, NASH and gastrointestinal diseases), where they specialize in in vivo pharmacology, peptide chemistry, molecular pharmacology, histology, stereology, NGS (next generation sequencing), bioinformatics and ex vivo assays.